Global Bacterial Vaginosis Drugs Market Trends, Size, Competitive Analysis and Forecast 2021-2027
The global bacterial vaginosis (BV) drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The rising incidence of bacterial vaginosis among women across the globe coupled with the surging demand for OTC products is augmenting the growth of the market. It is a vaginal disorder that produces vaginal discharge on account of an overgrowth of certain kinds of bacteria in the vagina. BV is a global concern due to the increased risk of the acquisition of sexually transmitted infections. BV can occur in any age group, however, globally it is more prevalent in females of reproductive age.
According to the American Sexual Health Association 2019,
BV is a common gynecologic infection, which affects nearly 29% of women in the
US. At least 15% of the sexually active population are suffering from BV; due
to this BV is three-four times more common than urinary tract infections (UTI).
Hence, the rising incidence of BV is leading to an upsurge in R&D for its
treatment by private manufacturers and research organizations. However, several
clinical trials are undergoing to enlarge the potential future of bacterial
vaginosis drugs.
To Request a Sample of our Report on Global Bacterial
Vaginosis Drugs Market: https://www.omrglobal.com/request-sample/bacterial-vaginosis-drugs-market
Key players of the market include Bayer AG, Pfizer
Inc., and Sanofi S.A., among others. The market players are eyeing to
strengthen their position in the market by adopting various strategies as
mergers and acquisitions, partnerships, collaborations, new product launch and
development in the existing product portfolio, and so on. For instance, in August
2020, DarĂ© Bioscience, Inc., one of the prominent leaders in women’s health
innovation, announced the publication of a proof of concept study of DARE-BV1
in Clinical and Experimental Obstetrics & Gynecology, an international
journal focused on the publication of high-quality scientific research related
to obstetrics and gynaecology and women’s health. DARE-BV1 is a novel
thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is
being evaluated as a one-time vaginally administered treatment for bacterial
vaginosis (BV).
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Bayer
AG, Pfizer Inc., and Sanofi S.A., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Bacterial Vaginosis Drugs Market is Available
at: https://www.omrglobal.com/industry-reports/bacterial-vaginosis-drugs-market
Global Bacterial Vaginosis Drugs Market by Segmentation
By Type
• Rx
• OTC
By Application
• Hospital
• Pharmacy
• Others
Global Bacterial Vaginosis Drugs Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment